SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing a massive surge in trading volume and investor interest as the community positions itself ahead of a critical May FDA decision for its ADHD drug, CTx-1301. Investors are actively discussing the potential impact of an anticipated U.S. patent approval on the stock, drawing parallels to previous market rallies while debating the impact of recent financing moves on the company's long-term valuation.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) remains a major focal point as investors debate whether mining stocks can decouple from volatile gold and silver spot prices amidst ongoing geopolitical tensions and fiscal policy shifts. The community is actively discussing Elliott Wave technical patterns, potential margin calls, and the broader macro implications of central bank activity on the metals complex.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to intensifying speculation surrounding its proprietary III-V-on-silicon photonics technology, which investors view as a critical, scalable solution for the power-efficiency bottlenecks in AI data centers. The community is actively discussing the stock's potential for high-volume commercial adoption, citing recent patent filings, government contracts, and the strategic addition of veteran industry leadership as key indicators that the company is transitioning from R&D to market-ready commercialization.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently under heavy scrutiny as investors weigh the impact of recent capital raises against anticipation for late-stage clinical trial results for its psilocybin-based treatment. While the community remains divided between those expressing frustration over share dilution and those holding for a potential long-term buyout or market-leading approval, technical traders are actively monitoring the stock's support levels as it consolidates near key psychological marks.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders closely monitor geopolitical instability in the Strait of Hormuz and rising oil prices, with the community actively debating whether current volatility metrics are being suppressed or if a major market correction is imminent. Investors remain divided, with many aggressively adding to positions as an insurance hedge against a potential global market pullback, while others caution against the structural decay inherent in leveraged volatility products.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is currently moving alongside fluctuations in natural gas futures as traders weigh the impact of seasonal shoulder season transitions against ongoing geopolitical risks in the Middle East. The community remains divided, with active discussions debating whether to play the potential for extreme volatility driven by supply chain disruptions or to bet on a return to fundamental bearish trends as warming weather forecasts emerge.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is capturing significant trader attention as the community debates its potential inclusion in upcoming payment initiatives, despite ongoing skepticism from bears regarding its long-term price action. While some investors see the current consolidation as a prime accumulation phase for a future breakout, others remain wary of repetitive dump patterns and frequent market volatility.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is seeing intense trading activity as market participants clash over conflicting narratives surrounding Middle East geopolitical disruptions and U.S. natural gas fundamentals. Community members are actively debating whether the ongoing supply-chain volatility in the Strait of Hormuz will trigger a sustained price breakout or if high storage levels and shoulder-season demand will ultimately lead to another technical collapse.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is facing intense community debate as investors weigh persistent price stagnation and frustration with leadership against the potential of its long-term ecosystem development and institutional integrations. While some participants are aggressively accumulating during current price levels, others are increasingly vocal about the lack of transparent progress and the asset's failure to decouple from broader market volatility.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is seeing heightened community engagement as traders react to the stock's high-beta correlation with Bitcoin and its ongoing transition into a crypto-focused treasury company. Discussion is currently polarized, with bulls pointing to the company's Bitcoin holdings and potential for long-term re-rating against net asset value, while bears frequently cite concerns over dilution, reverse splits, and the high costs of operational debt.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Ondas said that Sentry CS has seen rapid growth, with combat-proven deployments across 25 countries, and has achieved fully operational threat mitigation.</li><li>The company expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.</li><li>Last week, Ondas announced a definitive agreement to acquire a controlling interest in 4M Defense, an Israeli smart demining company specializing in advanced demining capabilities.</li></ul>Ondas Holdings Inc. (ONDS) became one of the top trending tickers on Stocktwits and the company’s shares rose 4% in early trading on Tuesday following the announcement that it has entered into a definitive agreement to acquire Sentry CS, an Israel-based company in Cyber-over-RF (CoRF) and Protocol-Manipulation counter-Unmanned Aerial Systems (UAS) technology."The addition of Sentrycs will strengthen our leadership in counter-UAS and solidify Ondas' position as a full-spectrum provider of autonomous defense solutions," said Eric Brock, Chairman and CEO of Ondas Holdings.&nbsp;Ondas expects the transaction to close in November 2025. The terms of the deal were not disclosed.Retail sentiment on Ondas jumped to ‘bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Sentry CS’ Technology</h2>Ondas said that Sentry CS has seen rapid growth, with combat-proven deployments across 25 countries, and has achieved fully operational threat mitigation."Passive RF detection and tracking are essential to modern layered defense, and Sentrycs brings a proven technology platform already deployed across sensitive airspace, critical infrastructure, and border environments,” Brock said.Brock added that by integrating Sentry CS with Ondas’ Iron Drone Raider system, the company expects to deliver a unified detect-to-defeat solution that addresses the rapidly evolving threat landscape for its defense and homeland security customers worldwide.<h2 class="st-heading-2">Ondas’ Recent Slew Of Acquisitions</h2>Last week, Ondas announced a definitive agreement to acquire a controlling interest in 4M Defense, an Israeli smart demining company specializing in advanced demining capabilities, including robotic systems with terrestrial and subsurface AI-powered intelligence technologies.Ondas had noted that 4M Defense will expand Ondas Autonomous Systems’ addressable market into the large global landmine and UXOs clearance and subsurface intelligence platforms market.The company had also announced the acquisition of a controlling interest in Insight Intelligent Sensors, an Israeli developer of AI-driven electro-optical sensing systems.<a href="https://stocktwits.com/symbol/ONDS">Shares of Ondas</a> have gained over 771% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dennys-620-million-deal-oppenheimer-says-not-expecting-competitive-bidding-process/cL28guSR36a">Denny's $620 Million Deal: Oppenheimer Says Not Expecting ‘Competitive Bidding Process’</a>

In this photo illustration, a person holds a smartphone displaying the logo of Ondas Holdings Inc. 

ONDS Stock Rises Following Acquisition Of Israel-Based Sentry CS

Ondas expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.

Equity

Ondas expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.


Time to fade momentum trade, Jefferies says

Investing.com -- The momentum factor weakened in December, but more downside can be expected in the first quarter, according to a Jefferies strategist.

Shares of Aquestive Therapeutics, Inc. (<a class="mention" data-mention="$AQST" data-symbol-id="AQST" href="https://stocktwits.com/symbol/AQST" target="_blank">$AQST</a>) traded flat early on Thursday, paring pre-market gains, amid a surge in retail chatter that pushed the stock into the top 10 trending tickers on Stocktwits.&nbsp;The company reported positive topline results from its Oral Allergy Syndrome (OAS) challenge study for its Anaphylm Sublingual Film.&nbsp;This study marks the final supportive adult trial in the Anaphylm development program ahead of discussions with the U.S. Food and Drug Administration (FDA).Both the primary and secondary endpoints of the study were successfully met, with no significant differences observed between Anaphylm’s pharmacokinetics (PK) in subjects with and without allergen exposure.&nbsp;The Tmax, or time to maximum plasma concentration, remained at 12 minutes in both groups, while the Cmax, or maximum plasma concentration, was consistent between them.&nbsp;The drug was also found to be safe and well-tolerated, with all adverse events reported as mild or moderate, resolving without medical intervention.On Stocktwits, retail sentiment for AQST surged into the ‘extremely bullish’ zone as of 9:30 am ET, accompanied by a sharp increase in message volume.<stembedurl>https://stocktwits.com/Outrageous/message/589944616</stembedurl><stembedurl>https://stocktwits.com/BioEmerging/message/589945926</stembedurl>A little over a week ago, H.C. Wainwright raised its price target on Aquestive Therapeutics to $10 from $9, maintaining a ‘Buy’ rating.&nbsp;The analyst cited the company’s virtual investor day, which provided insights into its technology platform, product development, and long-term strategy.Last month, Aquestive highlighted its Anaphylm Sublingual Film and AQST-108 Topical Gel during the event, both emerging from the company’s Adrenaverse epinephrine prodrug platform.&nbsp;CEO Daniel Barber expressed optimism about the company’s pipeline, mentioning that they had submitted a pre-NDA meeting request to the FDA for Anaphylm and were on track to report topline data from the OAS study.Looking ahead, the company expects to hold a pre-Investigational New Drug (IND) meeting with the FDA in Q1 2025 and plans to begin a Phase 2 study for AQST-108, targeting alopecia areata, in the second half of 2025, pending FDA alignment.Aquestive’s stock has gained over 160% year-to-date.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-stock-jumps-after-q3-earnings-beat/cJ218ORR7f">Viking Therapeutics Stock Jumps After Q3 Earnings Beat: Retail Stays Cheerful</a>

Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success

This study marks the final supportive adult trial in the Anaphylm development program ahead of discussions with the U.S. FDA.

DWAS
Invesco Dorsey Wright SmallCap Momentum ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DWAS News

DWASInvesco Dorsey Wright SmallCap Momentum ETF